Harvard University
Harvard University Biostatistics Working Paper Series
Year 

Paper 

Quantifying the totality of treatment effect
with multiple event-time observations in the
presence of a terminal event from a
comparative clinical study
Brian Claggett∗

Lu Tian†

Scott D. Solomon∗∗

∗

Haoda Fu‡
L. J. Wei††

Harvard Medical School, bclaggett@partners.org
Stanford University School of Medicine, lutian@stanford.edu
‡
Eli Lilly, haoda-fu@lilly.com
∗∗
Harvard Medical School, ssolomon@bwh.harvard.edu
††
Harvard University, wei@hsph.harvard.edu
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder.
†

http://biostats.bepress.com/harvardbiostat/paper212
Copyright c 2017 by the authors.

Quantifying the totality of treatment effect
with multiple event-time observations in the
presence of a terminal event from a
comparative clinical study
Brian Claggett, Lu Tian, Haoda Fu, Scott D. Solomon, and L. J. Wei

Abstract

To evaluate the totality of one treatment’s benefit/risk profile relative to an alternative treatment via a longitudinal comparative clinical study, the timing and occurrence of multiple clinical events are typically collected during the patient’s followup. These multiple observations reflect the patient’s disease progression/burden
over time. The standard practice is to create a composite endpoint from the multiple outcomes, the timing of the occurrence of the first clinical event, to evaluate
the treatment via the standard survival analysis techniques. By ignoring all events
after the composite outcome, this type of assessment may not be ideal. Various
parametric or semi-parametric procedures have been extensively discussed in the
literature for the purposes of analyzing multiple event-time data. Many existing
methods were developed based on extensive model assumptions. When the model
assumptions are not plausible, the resulting inferences for the treatment effect
may be misleading. In this article, we propose a simple, non-parametric inference
procedure to quantify the treatment effect which has an intuitive, clinically meaningful interpretation. We use the data from a cardiovascular clinical trial for heart
failure to illustrate the procedure. A simulation study is also conducted to evaluate
the performance of the new proposal.
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Abstract
To evaluate the totality of one treatment’s benefit/risk profile relative to
an alternative treatment via a longitudinal comparative clinical study, the timing and occurrence of multiple clinical events are typically collected during the
patient’s followup. These multiple observations reflect the patient’s disease
progression/burden over time. The standard practice is to create a composite endpoint from the multiple outcomes, the timing of the occurrence of the
first clinical event, to evaluate the treatment via the standard survival analysis
techniques. By ignoring all events after the composite outcome, this type of assessment may not be ideal. Various parametric or semi-parametric procedures
have been extensively discussed in the literature for the purposes of analyzing
multiple event-time data. Many existing methods were developed based on extensive model assumptions. When the model assumptions are not plausible, the
resulting inferences for the treatment effect may be misleading. In this article,
we propose a simple, non-parametric inference procedure to quantify the treatment effect which has an intuitive, clinically meaningful interpretation. We
use the data from a cardiovascular clinical trial for heart failure to illustrate
the procedure. A simulation study is also conducted to evaluate the performance of the new proposal.

Clinical Trials; Composite Endpoint; Multiple

Outcomes; Non-Parametric Estimation; Counting process; Survival analysis;
Wei-Lin-Weissfeld procedure.

1

Introduction

In a longitudinal clinical study, each patient may experience any of several clinical
events at various time points during the follow-up period. Such multiple event-time
observations provide a temporal profile of the patients disease burden or progression.
2
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An important question is how to utilize these observations collectively, for instance,
to evaluate a new therapy vs. the standard care from a risk-benefit perspective. A
common practice is to consider either the time from enrollment or randomization
to a specific event or to the first occurrence of one of a collection of pre-specified
clinical events as the study’s primary endpoint and to then analyze such data using
standard inference procedures from survival analysis. Such approaches, however, may
not utilize all relevant information to fully answer the clinical question of interest.
As an example, a randomized, comparative clinical trial, “Beta-Blocker Evaluation of Survival Trial (BEST),” was conducted to evaluate whether the beta-blocking
drug, bucindolol, would benefit patients with advanced chronic heart failure (BEST,
2001). For this study, there were 2708 patients enrolled, randomized to receive either
placebo or the beta-blocker, who were then followed for an average of two years. The
patients overall survival time was chosen as the primary endpoint of the study. For
the comparison of the two treatment groups, the p-value of the two-sample logrank
test was 0.11 with the 0.95 confidence interval for the hazard ratio of (0.78, 1.02),
numerically, but not significantly, in favor of the beta-blocker. Although mortality is
an important endpoint, an evaluation of the beta-blockers benefits and risks should
also include morbidity for chronic heart failure patients over the course of the study.
Clinically important morbidity events for these patients are, for instance, hospitalization for worsening heart failure (WHF), non-heart failure hospitalization (NHFH),
myocardial infarction (MI), and heart transplant (HT). The BEST study is a typical cardiovascular trial for which the times to non-fatal events prior to a terminal
event (for example, death) can be potentially observed for each patient. If we follow the conventional approach using a composite endpoint, that is, the time of the
first occurrence of any of the above five distinct events as the endpoint, the resulting
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Kalpan-Meier curves for two arms are given in Figure 1. The 0.95 confidence interval for the hazard ratio is (0.85, 1.02) and the p-value of the logrank test is 0.10.
Furthermore, if we consider the distribution of each specific component event, it is
apparent that the composite event is more often an occurrence of non-heart failure
hospitalization and less often worsening heart failure in the bucindolol arm (Table
1), even though each of these types of events occurs in fewer patients randomized to
bucindolol than in patients randomized to placebo. Like the results from the mortality analysis, the beta-blocker has only modest statistical evidence of benefit in this
population with respect to this composite outcome.
Table 1: Total number of patients experiencing each type of event, and specific type
of clinical events represented by the composite outcome, by treatment group
Event type
Placebo Bucindolol
Worsening HF
569 (42%) 476 (35%)
Non-HF Hosp
634 (47%) 619 (46%)
Death
449 (33%) 411 (30%)
MI
85 (6%)
46 (3%)
Transplant
41 (3%)
29 (2%)
Composite
971 (72%) 931 (69%)
Composite event type
Worsening HF
393 (40%)
Non-HF Hosp
445 (46%)
Death
99 (10%)
MI
32 (3%)
Transplant
2 (<1%)
Total
971

341 (37%)
466 (50%)
103 (11%)
18 (2%)
3 (<1%)
931

If the clinical questions regarding the risks and benefits of bucindolol extend beyond the simple analysis of mortality or of the occurrence of the first composite event,
several novel statistical procedures for comparing two groups may be used to analyze
such multiple event time observations (Wei et al., 1989; Li and Lagakos, 1998; Wang
4
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Figure 1: Time to first occurrence of worsening heart failure, non-HF hospitalization,
heart transplant, myocardial infarction, or death.

et al., 2001; Wang and Chiang, 2002; Ghosh and Lin, 2003; Lin et al., 2000; Huang and
Wang, 2011; Wang and Huang, 2014). These methods generally utilize model-based
parameters to quantify the between-group difference. As is the case with univariate survival analysis, when the model assumptions are not plausible, the resulting
estimates for the parameters may be difficult to interpret clinically (Kalbfleisch and
Prentice, 1981; Struthers and Kalbfleisch, 1986; Lin and Wei, 1989; Hernán, 2010;
Uno et al., 2014, 2015).
In this article, in order to include both mortality and morbidity events beyond
the first composite endpoint, we consider the patient’s endpoint based on a reverse
counting process, R(t) over time t, which provides the profile of the multiple event

5
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times that comprise the composite outcome above. For example, with the aforementioned five clinical events: WHF, NHFH, MI, HT, and death, in the BEST study,
Figure 2 shows several realizations of the R(·) process. Each realization is a downward step function starting with a y-axis value of 5, the number of distinct types of
event under consideration. At the time of an occurrence of a non-terminal (non-fatal)
event, R(·) drops by one unit, but at the time of the terminal event, R(·) drops to
zero. At a specific time t, R(t) represents the number of the composite events not
experienced at t. The area under this step function at t, A(t), is the sum of five
event-free survival times up to t. For example, for the first realization of R(·) in Figure 2, the observed A(48) is 118 (months). That is, this patient enjoyed 10 months of
HF-free survival, 18 months free of MI-free survival, 30 months of HT-free survival,
30 months of NHFH-free survival, and 30 months of overall survival. The cumulative
total of these is 118 months of event-free survival. Noting that the ideal case of a
patient without any increase in disease burden over the study period of interest (i.e.
here, 48 months) would correspond to A(48) = 240(= 48 × 5) months, this particular
patient experienced 49%(= 118/240) of the maximum possible cumulative event-free
survival, or conversely, 51%(= 1 − 118/240) of the maximum possible disease burden
over this time period, as measured by this combination of morbidity and mortality.
The values A(t) or the above ratio, P (t), for example, would be clinically meaningful
summaries for the temporal profile of patient health with regards to these multiple
event times up to time t. Note that for the second realization in Figure 2, only one of
the five outcomes is observed prior to the patient’s censoring at month 30. For this
patient, A(48) is not fully observed, but the available partial information indicates
that A(48) ∈ (140, 212] months (140 if the patient died the day after censoring; 212 if
the patient experienced no subsequent events until month 48) and P (48) is between

6
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0.12 and 0.42. It is important to note that in the presence of a terminal event such as
death, the standard forward counting process as the patient’s endpoint is problematic,
since this process is not well defined after death.
For the comparison of two groups, the difference or ratio of the two expected values E(R(t)), E(A(t)), or E(P (t)) is a clinically interpretable, model-free summary to
quantify the between-group contrast. In this paper, we present inference procedures
for handling one- and two-sample problems. All of the proposals are illustrated with
the data from the BEST study. Note that for the case with a single event time observation for each patient, E(R(t)) reduces to the survival rate S(t) and E(A(t)) is the
so-called restricted mean survival time at time t, which has been extensively studied,
for example, by Karrison (1987); Zucker (1998); Royston and Parmar (2011); Zhao
et al. (2012); Tian et al. (2014); Uno et al. (2014); Trinquart et al. (2016); A’Hern
(2016).

Furthermore, classical methods such as Andersen and Gill (1982); Fine

and Gray (1999); Lin et al. (2000) either treat the terminal events as censoring, consider the patient to be at risk for non-fatal events even after death, or extrapolate
the counting process of nonfatal and terminal events by assuming that there is no
nonfatal event after death. The validity of the former approach relies on the noninformative censoring assumption, which unrealistically assumes that the terminal
event is independent of the non-fatal events during the follow-up. The latter does
not differentiate nonfatal from terminal events and may yield misleading comparisons
when the mortality rate is very different between two groups. For example, the low
incidence rate of one arm may reflect higher mortality rate rather than a real clinical
benefit. Other methods such as Liu et al. (2004); Rondeau et al. (2007) explicitly
model the joint distribution of non-fatal and terminal events and produce estimators
of the treatment effect on non-fatal and fatal events separately. These methods are

7
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heavily model-dependent and it is difficult to combine the two estimates into a single
summary in a setting of binary decision making. Mao and Lin (2016) recently proposed a semiparametric model for a composite outcome based on pre-specified weights
for different types of events, relying on an assumption of multiplicative effects on the
marginal rate function.

2

One- and two-sample inference procedures

Suppose that for each study subject, there are (K + 1) distinct types of events of
interest, which can be potentially observed during the study follow-up. Also assume
that the (K + 1)th event is the only terminal event. Let R(·) be the reverse counting
process described in the Introduction with respect to these K + 1 events. In this Section, we are interested in making inferences about the parameters E(R(·)), E(A(·)),
and E(P (·)). Now, let Tk , k = 1, · · · , K + 1, be the minimum of T̃k and T̃K+1 , where
T̃k is the time to the first occurrence of the kth type of event. Then,

R(t) =

K+1
X

I(Tk ≥ t),

(2.1)

k=1

where I(·) is the indicator function,

A(t) =

K+1
X

Ak (t),

(2.2)

k=1

where Ak (t) is the minimum of Tk and t, and
P (t) = 1 −

A(t)
.
t(K + 1)

(2.3)

8
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Figure 2: Profile of observed data from three hypothetical patients from randomization to end of follow-up.
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Note that E(Ak (t)) is the restricted mean survival time up to time t for Tk , which is
the area under the survival curve for Tk up to time t.
The above processes may not be observed completely if the terminal event time
T̃K+1 is censored by a random variable C, which is assumed to be independent of T̃K+1 ,
as well as the non-terminal event times T̃1 , . . . , T̃K . Let Xk be the minimum of Tk and
¯ = 1 if T̃K+1
C, ∆k = 1 if Tk is observed and zero, otherwise, for k = 1, · · · , K, and ∆
¯ i) + τ ∗∆
¯ i }, ∆
¯ i ),
is observed and zero, otherwise. The data, ({Ri (t), 0 ≤ t ≤ Ci (1 − ∆
i = 1, · · · , n, where τ ∗ is the maximum study followup time, consist of n independent
¯ ∆).
¯
¯ + τ ∗ ∆},
copies of ({R(t), 0 ≤ t ≤ C(1 − ∆)
Using (2.1-2.3), E(R(t)), E(P (t)), and E(A(t)) can be consistently estimated with
these n sets of possibly incomplete observations by

[
E(R)(t)
=

K+1
X

Ŝk (t),

(2.4)

k=1

where Ŝk (·) is the Kaplan-Meier (KM) estimate for Tk based on {Xik , ∆ik , i = 1, · · · , n}
for k = 1, · · · , K + 1; and

[
E(A)(t)
=

K+1
X

\
E(A
k )(t),

(2.5)

k=1

\
where E(A
k )(t) is the area under the KM curve Ŝk (·) up to time t.
It is important to note that although the censoring variable C is assumed to be
independent of all the event times, the outcome processes R(t), A(t), and P (t) may
be correlated with C. Such an induced dependence results in some technical difficulty
[
[
for deriving the large sample properties of E(R)(·)
and E(A)(·)
(Glasziou et al., 1990;
Lin, 2003). For the present case, due to the decompositions (2.4) and (2.5), one may
10
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use similar techniques, for example, as in Wei et al. (1989); Li and Lagakos (1998). to
justify the large sample mean-zero Gaussian approximations to the distributions of
[
[
{E(R)(t)−E(R)(t)}
and {E(A)(t)−E(A)(t)}
as processes over time, such that t ≤ τ ,
pr(Xk > τ ) > 0 for all k . In practice, approximations to these distributions can be
obtained via a perturbation-resampling method. Specifically, a perturbed version of
each KM estimate is
"
Sk∗ (t) = exp −

n Z
X
i=1

t

0

Vi d{I(u ≤ Tik )∆ik }
Pn
l=1 Vl I(Xlk ≥ u)

#
(2.6)

where t ≤ τ , and {Vi : i = 1, . . . n} is a random sample of size n from the standard exponential distribution. For each realization of random weights {Vi }, let
P ∗
P \
∗ )(t) =
∗
∗
∗
\
\
\
E(R
k Sk (t), and E(A )(t) =
k E(A )k (t), where E(A )k (t) is the area
under the KM curve Sk∗ (·) up to time t (Royston and Parmar, 2011; Zhao et al., 2012;
√
\ − E(R)(·)} can be approxTian et al., 2014). Then the distribution of n{E(R)(·)
√
∗ )(·) − E(R)(·)}
\
\ with a large number, M , of
imated by the distribution of n{E(R
realizations of random weights {Vi }. Denote the observed variance as σ̂R2 (·). Similarly,
√
\ − E(A)(·)} can be approximated by the distribution
the distribution of n{E(A)(·)
√ \
∗ )(·) − E(A)(·)}
\ with the corresponding variance estimate σ̂ 2 (·). Thus, a
of n{E(A
A
(1 − α) confidence interval for E(R)(·), for t ≤ τ, is given by


−1/2
−1/2
\
\
E(R)(·) − z1−α/2 n
σ̂R (·), E(R)(·) + z1−α/2 n
σ̂R (·) ,
where z1−α/2 is the (1 − α/2)th quantile of the standard normal distribution. To
preserve the range of E(R)(·) ∈ [0, K + 1], we may also first construct a confidence
interval of g −1 (E(R)(·)) based on the proposed perturbation method and then transform the resulting confidence interval using g(·) to obtain an appropriate confidence
11
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interval for E(R)(·), where g(·) is a given monotone function (−∞, +∞) → [0, K +1].
Similarly, a (1 − α) confidence interval for E(A)(·) is given by


−1/2
−1/2
\
\
E(A)(·) − z1−α/2 n
σ̂A (·), E(A)(·) + z1−α/2 n
σ̂A (·) .
This resampling technique has been utilized in dealing with various survival analysis
problems (Park and Wei, 2003; Cai et al., 2010).
Now, suppose we are interested in constructing a simultaneous confidence band
for E(R)(·) or E(A)(·) over a specific range t ∈ [a, b], where a is larger than the first
observed event time and b is smaller than the largest observed follow-up time. The
equal precision (1 − α) confidence bands (Gilbert et al., 2002) can be constructed by


−1/2
−1/2
\
\
E(R)(·) − cα n
σ̂R (·), E(R)(·) + cα n
σ̂R (·)
and


−1/2
−1/2
\ − dα n
\ + dα n
E(A)(·)
σ̂A (·), E(A)(·)
σ̂A (·) ,
where cα is chosen such that

∗ )(t) − E(R)(t)
\
[
E(R
pr sup
> cα = α,
σ̂R (t)
t∈[a,b]


and dα is chosen such that

∗ )(t) − E(A)(t)
\
[
E(A
pr sup
> dα = α.
σ̂A (t)
t∈[a,b]


With the data from the placebo arm of the BEST study for the five distinct
[
events discussed in the Introduction, Figure 3 gives the estimate E(R)(t)
with the
12
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0.95 pointwise confidence intervals and simultaneous confidence bands for E(R)(t) for
1 ≤ t ≤ 48 months based on M = 500 sets of perturbed data. These bands are quite
informative; for example, in the placebo group, at t = 48 months, on average, there are
2.00 events not occurring before the death with a 0.95 pointwise confidence interval of
[
(1.81, 2.18). The estimated sum of all the event-free survival times, E(A)(48),
is 150.8
months with a 0.95 confidence interval of (146.8, 154.8) months. Correspondingly, the
[)(48) is
estimated proportion of maximum morbidity/mortality experienced was E(P
0.372 (0.355, 0.388).
Now, if we are interested in making inferences about the difference DR (·) of
\
E(Rj )(·) between two treatment groups j(= 0, 1), the resulting D̂R (·) = E(R
1 )(·) −
\
\
E(R
0 )(·) can be obtained via the corresponding empirical counterparts, E(Rj )(·). The
distribution of D̂R (·) can be approximated via the aforementioned resampling method.
Our procedure is an extension of the proposal by Parzen et al. (1997) for the case with
the univariate event time observations. The difference DA (t) of two E(A)(t)’s can be
\
\
estimated by its counterpart via D̂A (t) = E(A
1 )(t) − E(A0 )(t). With the data from
the BEST study, Figure 4 shows the estimated Ê(R)(·) process for both bucindolol
and the placebo groups, along with the corresponding contrast D̂R (·) between the
beta-blocker and the control arms. At t = 24 months, the estimated difference is 0.19
events with a 0.95 confidence interval of (0.03, 0.36). At t = 48 months, the estimated
difference is 0.18 but with a wider 0.95 confidence interval of (-0.09, 0.46). Note that
for each of these comparisons, no information is used regarding the temporal profile
of events occurring prior to the selected time point. In order to utilize both the occurrence and the timing of the events, we may used the estimated cumulative difference
in total event-free survival time DA (t). At the end of followup, this is 7.6 months with
a 0.95 confidence interval of (1.5, 13.7) months, demonstrating a significant overall

13
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beneficial effect of the active therapy over placebo. Alternatively, this overall treat\
\
ment difference can be expressed as R̂A (t) = E(A
1 )(t)/E(A0 )(t) = 1.05(1.01, 1.09),
indicating an estimated 5% increase in event-free survival time, with p = 0.015 for the
test of equality between treatment groups. Another interesting expression is via the
comparison of the proportion of follow-up time lost to morbidity and mortality, Pj (t).
\
\
The ratio of these two estimates R̂P (t) = E(P
1 )(t)/E(P0 )(t) = 0.92 (0.85, 0.98), an
8% decrease in morbidity/mortality.

3

Simulations

[
In order to assess the properties of the proposed area under the curve, E(A)(t),
for the
purpose of comparing two treatment groups, we performed an extensive simulation,
intended to mimic a trial setting similar to that of the BEST trial. In the simulations
below, we consider a trial with N = 1500 patients followed for a maximum time τ of 4
years, in which there are a total of four clinical event of interest: three non-fatal events
in addition to all-cause mortality. In all scenarios, the event times in the placebo
group are drawn from Weibull distributions with shape parameter 0.8, and scale
parameters 2000, 3000, and 4000 for the non-fatal event and 8000 for the fatal events,
which correspond to survival probabilities of 46%, 57%, 64%, and 77%, respectively,
at the end of the follow-up period. In order to reflect the common scenario in which
event times are correlated within patients, we induce a shared frailty parameter drawn
from a gamma distribution with an unit mean and variance = 2 (Liu et al., 2004;
Rondeau et al., 2007, 2013). In Scenario 0, the treatment has no effect on any of the
four clinical outcomes, representing the null hypothesis. We then consider treatment
effects which reduce time lost to morbidity/mortality by either 10% (moderate effect)

14
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Figure 3: Point and interval estimates of E(R)(t) over time from the placebo arm of
the BEST trial. Solid curve represents point estimates, with 0.95 pointwise and simultaneous confidence intervals denoted by dashed lines and gray shading, respectively.

or 20% (strong effect). In Scenario 1, the treatment effect is strong with respect to
the two more frequent non-fatal events, but moderate for the other two events. In
Scenario 2, the treatment effect is strong with respect to the two less frequent events,
but moderate for the more frequent events. In Scenario 3, the treatment effect is
strong with respect to all 4 events. Within each scenario, we considered that the
treatment effect may manifest itself through a constant reduction in hazard, (i.e.
15

Hosted by The Berkeley Electronic Press

Two-Sample Comparison

0.2

^ (⋅)
D
R

3

-0.2

1

0.0

2

Reverse Counting Process

0.4

4

5

0.6

Two-Sample Comparison

0

Placebo
Bucindolol
0

6

12

18

24

30

36

42

48

0

6

Months from Randomization

12

18

24

30

36

42

48

Months from Randomization

Figure 4: Left: Estimated number of events not yet experienced in each treatment
arm. Right: Treatment effect D̂R (·) as a function of follow-up time. Solid curve
represents point estimates, with 0.95 pointwise and intervals denoted by dashed lines.

the shape parameter remains constant, and the scale parameters is increased in the
treated arm, PH assumption), or alternatively, through a delay in event times, such
that the treatment and control groups’ survival curves become equal at the end of
the study, but the treatment group’s survival curve is uniformly above the control
group’s for the duration of the study (i.e. the shape parameter is increased in the
treated arm, non-PH assumption). We assume independent administrative censoring,
reflecting a hypothetical 5-year trial with 3 years of uniform enrollment, so that every
patient is followed for at least two years. We compare the proposed method to the
traditional “time-to-first” composite outcome compared via the log-rank test. The
Table below shows the proportion of simulated data sets in which the null hypothesis
of no treatment effect is rejected at the α = 0.05 level.
In Scenario 0, we find that type-I error is well controlled. In Scenarios 1-3, we see
16
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Table 2: Two-Sample Power
Scenario

Treatment Effect

Treatment Effect

Proportional

Method 1:

Method 2:

Frequent Events

Less Frequent Events

Hazards

RCP

LR (first event)

0
1

none
strong

none
moderate

2

moderate

strong

3

strong

strong

Yes
Yes
No
Yes
No
Yes
No

5%
34%
45%
48%
54%
70%
76%

5%
34%
44%
22%
28%
56%
63%

that the proposed metric has equal or greater power than the standard “time-to-first”
event approach in all settings, particularly when the treatment effect is strong with
respect to the fatal events and when the PH assumption does not hold.

4

Discussion

Although many statistical methods are currently available to compare two treatment
groups in the presence of multiple outcomes, a method that is not dependent on
a particular parametric modeling assumption is preferable. The ability to produce
estimates of treatment effects which cannot be undermined by model misspecification
should be seen as a benefit to investigators, sponsors, and regulators, each of whom
rely on the robustness of the inferences drawn from clinical studies. Moreover, an
intuitive and interpretable measure of the magnitude of treatment effect expressed
in concrete terms such the numbers of days spent event-free or the number of events
prevented is quite attractive. For example, the constant intensity or rate function
model for recurrent event times (Andersen and Gill, 1982; Lin et al., 2000) may be
theoretically interesting, but the results are difficult to interpret, especially when the
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model assumption is violated.
The methods proposed in this article represent extensions of relatively standard
concepts in the analysis of survival data to address to an important open question in
the general community of clinical trialists. We note that under certain circumstances,
it may be desirable to modify the starting value of the reverse counting process or
the relative values of the individual events in the reverse counting process R(0). For
example, reducing the starting value to R(0) = 1 results in a conventional “time-tofirst-event” analysis. One may also desire to implement weights wk associated with
each of the K + 1 event types, similar to ad-hoc procedures which have appeared in
the clinical literature (Armstrong et al., 2011).
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